Natulan (Procarbazine Hydrochloride)

Natulan (procarbazine hydrochloride) is used as an antineoplastic agent in several lymphoid and solid‑tumour indications.

• Hodgkin lymphoma: contributes to disease remission when combined with other chemotherapy agents.
• Brain tumors (e.g., glioma): provides cytotoxic activity against malignant glial cells.
• Other lymphomas: used as part of multi‑drug regimens to achieve tumour control.

• Procarbazine hydrochloride exerts its antineoplastic effect by alkylating DNA bases, which leads to cross‑linking of DNA strands and inhibition of DNA, RNA and protein synthesis. This disruption impairs cell replication and triggers apoptosis in rapidly dividing cancer cells, particularly those of lymphoid and neuro‑ectodermal origin.

Procarbazine hydrochloride may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Fatigue: persistent tiredness affecting daily activities.
• Loss of appetite: reduced desire to eat.
• Mild leukopenia: slight decrease in white blood cell count.
• Mild anemia: modest reduction in red blood cells.
• Vomiting: occasional episodes of emesis.

Serious or Rare Side Effects

• Severe bone‑marrow suppression: profound pancytopenia requiring medical intervention.
• Secondary malignancies: increased risk of therapy‑related cancers.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Severe infection: opportunistic infections due to immunosuppression.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Neurotoxicity: peripheral neuropathy or seizures in rare cases.

Procarbazine requires careful monitoring and specific safety measures.

• Pregnancy: Category D – avoid use unless benefits outweigh risks.
• Blood monitoring: regular complete blood counts to detect myelosuppression.
• Liver function: assess hepatic enzymes before and during therapy.
• Concomitant myelosuppressive drugs: avoid or adjust dosing to reduce cumulative toxicity.
• Renal impairment: use with caution and consider dose adjustment.
• Store below 25°C: keep in the original pack, protect from moisture.

Procarbazine can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• MAO inhibitors: risk of hypertensive crisis.
• Other alkylating agents: additive bone‑marrow suppression.
• Warfarin: potentiation of anticoagulant effect leading to bleeding.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine): may increase procarbazine plasma levels.
• Antacids containing aluminum or magnesium: could affect absorption.
• Live vaccines: reduced vaccine efficacy due to immunosuppression.